Concepedia

Vijay Peddareddigari

VP

21

Publications

2.7K

Citations

19

H-Index

2010

Active since

Affiliations

Autolus (United Kingdom)(Current)

University College London

University College London Hospitals NHS Foundation Trust

Sarah Cannon

The University of Texas MD Anderson Cancer Center

Vijay Peddareddigari is an author at Autolus (United Kingdom) specializing in medicine, pathology, and cancer research.

Top concepts

Publications per year

2010–2023

21

Publications

21

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook et al. · The Lancet Oncology · 2012 · 554 citations

, , +7

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante et al. · The Lancet Oncology · 2012 · 534 citations · Full text

, , +9

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann et al. · Journal of Clinical Oncology · 2015 · 371 citations

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

Shaun Cordoba, Shimobi Onuoha, Simon Thomas et al. · Nature Medicine · 2021 · 260 citations · Full text

The Tumor Microenvironment in Colorectal Carcinogenesis

Vijay Peddareddigari, Dingzhi Wang, Raymond N. DuBois · Cancer Microenvironment · 2010 · 250 citations · Full text

, , +5

Rows per page

1–5 of 21